Shenzhen Salubris Pharmaceuticals Announces Investment and In-Licensing Agreement With MedAlliance to Bring Novel Cardiovascular Disease Therapy to China | Business Wire

Splendris International Limited, an affiliate of Shenzhen Salubris Pharmaceuticals Co Ltd. (Salubris), a multi-national leader in the development and commercialization of cardiovascular products in China and beyond, today announced a strategic investment and in-licensing agreement with Swiss cardiovascular pioneer M.A. MedAlliance S.A. (MedAlliance). Under the terms of the agreement, Salubris will make a $20 million equity investment in MedAlliance and will commit an additional $10 million in developmental milestones in exchange for exclusive rights to develop and commercialize MedAlliance’s lead investigational product Selution, a potential best-in-class sirolimus micro-reservoir drug-coated balloon (DCB), for peripheral and cardiovascular applications in the Chinese market. MedAlliance will also be eligible for royalty payments on sales.

@ Business Wire | May 21, 2018

161 thoughts on “Shenzhen Salubris Pharmaceuticals Announces Investment and In-Licensing Agreement With MedAlliance to Bring Novel Cardiovascular Disease Therapy to China | Business Wire”

Leave a Reply

Your email address will not be published. Required fields are marked *